MRK Merck & Co. Inc.

Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities

The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the Foundation over five years, Bridging the Gap will build sustainable partnerships across sectors to support innovative approaches to diabetes treatment and management.

Bridging the Gap partners will work to ensure that individuals with diabetes can benefit not only from improved medical care, but also from interventions that address the multiple social and environmental factors outside of the health care system that influence health and well-being.

“Diabetes is a significant population health concern, with more than 29 million Americans living with the disease. There is a higher prevalence of diabetes in underserved communities, where many patients do not receive the help they need to effectively manage their health,” said Dr. Julie L. Gerberding, chief patient officer, Merck and chief executive officer, Merck Foundation. “Through Bridging the Gap, we will work with our partners to promote sustainable improvements in diabetes care for those who need it the most.”

Non-profit organizations in the United States are invited to apply for a grant to support the implementation of multifaceted programs focused on type 2 diabetes that will:

  • Transform the delivery of primary care to improve diabetes management for vulnerable and underserved populations.
  • Use intersectoral collaborations to address factors inside and outside of the health care system that influence diabetes outcomes.
  • Improve health outcomes for individuals with type 2 diabetes, such as improved glucose and lipid control.

As part of Bridging the Gap, the Foundation will support a comprehensive evaluation to assess the impact of the initiative and identify novel intersectoral approaches to reduce diabetes disparities.

Interested organizations can learn more about the application process, eligibility requirements, guidance for proposed interventions and deadlines from the Foundation’s Call for Proposals on our website.

An external advisory committee will review the invited proposals based on specific criteria outlined in the Call for Proposals. Grant awards will be announced in mid-2017.

About The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company and is Merck’s chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Merck Foundation has contributed more than $844 million to support important initiatives that address societal needs and are consistent with Merck’s overall mission to help the world be well. For more information, visit www.merckgiving.com.

EN
17/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merck & Co. Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 7,085 shares at 87.000USD and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch